Research programme: plasma-derived biopharmaceuticals - ProMetic Life Sciences/ProThera Biologics

Drug Profile

Research programme: plasma-derived biopharmaceuticals - ProMetic Life Sciences/ProThera Biologics

Alternative Names: IaIp - Prometic Life Sciences; Inter alpha-one inhibitor proteins; Inter-alpha inhibitor proteins - Prometic Life Sciences

Latest Information Update: 06 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProMetic Life Sciences; ProThera Biologics
  • Class Anti-inflammatories; Proteins
  • Mechanism of Action Serine protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute enterocolitis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute enterocolitis
  • Research Inflammation

Most Recent Events

  • 05 Mar 2018 The US FDA grants a Rare Pediatric Disease Designation to inter alpha inhibitor proteins for Acute enterocolitis
  • 15 Feb 2018 Preclinical trials in Acute enterocolitis in USA (unspecified route)
  • 15 Feb 2018 Inter alpha inhibitor proteins receives Orphan Drug status for Acute enterocolitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top